Kemwell Biopharma has acquired Cirrus Pharmaceuticals Inc. Cirrus has development expertise in inhalation, parenteral, transdermal, topical and liquid dosage forms, and offers stand-alone analytical services including stability studies. Financial terms were not disclosed.
 
“Kemwell’s corporate objective is to build a leading global bio/pharmaceutical contract services company,” said Anurag Bagaria, chairman and managing director of Kemwell. “Cirrus will complement the existing contract services offered by Kemwell with early stage innovative product development. Kemwell will now provide customers with a complete solution from early development in the U.S. to commercial manufacturing in Kemwell’s EMA, FDA and PMDA approved facilities in India and Sweden.”
 
Cirrus president Dr. Anthony Hickey commented, “This acquisition is a testament to the tremendous value our talented employees have created for Cirrus over the past several years. The acquisition will transform Cirrus into a global player in R&D services by significantly strengthening our capabilities in inhalation R&D and increasing offerings in other areas such as oral solids dosage forms. The Cirrus team looks forward to joining the Kemwell family and continuing to provide the high customer satisfaction it always has.”